Hikma Pharmaceuticals (LON:HIK) cover image
116 Reads (2 mins read)

Finding long-term winners: 5 things in favour of Hikma Pharmaceuticals

4th Jun by Michael Green

If, as an investor, you’re only looking at sales and earnings growth, there's a chance that a vital question is not being asked: how is that growth being funded?

Top analysts and investors such as Warren Buffett and Michael Mauboussin say capital allocation - the deployment of company time, money, ideas, and people - is the key to building moat-like quality and profitability characteristics. This is important as moat characteristics are perhaps the most fundamental driver of future share price performance. 

In other words, if you find a company that consistently allocates its capital profitably, chances are you are onto a long-term winner with strong economic moats. Hikma Pharmaceuticals might be one such company.

GET MORE DATA-DRIVEN INSIGHTS INTO LON:HIK »

Screening for upwardly mobile, high quality companies

Using a ratio such as return on equity (ROE) is useful to determine how well and efficiently a company is deploying its capital. It is calculated by dividing net income by book value of equity.

It’s no coincidence that Buffett is a fan of the measure - many companies with high ROEs tend to exhibit the high-quality, moat-like business traits that he is so fond of gaining exposure to.

One of the stocks that currently exhibits a high ROE is Hikma Pharmaceuticals. The group has:

Stocks exhibiting these traits are typically a solid mix of quality and momentum. We can see this with Hikma Pharmaceuticals, which has a Quality Rank of 72 and a Momentum Rank of 99.

To find high ROE stocks whose fantastic business models are being rewarded by the market, it is best to use a stock screen that selects only stocks with both positive one-year relative strength and upgraded current year broker forecasts. The former ensures these shares have been outperforming the market and the latter suggests outperformance can continue.

Studies indicate that combining factors such as Value, Quality and Momentum is a more effective way of outperforming the market over longer time frames. That's why we have constructed our StockReports to give an instant impression of how well exposed Hikma Pharmaceuticals (LON:HIK) is to these three factors. We go into greater detail on factor investing in this video

Stockopedia helps you to identify return-enhancing factors such as Quality, Value and Momentum by analysing thousands of data points every day. To find out more about you find investment opportunities and analyse your portfolios then take one of our two-week free trials and have a look around.

Share this article
As per our Terms of Use, Stockopedia is a financial news & data site, discussion forum and content aggregator. Our site should be used for educational & informational purposes only. We do not provide investment advice, recommendations or views as to whether an investment or strategy is suited to the investment needs of a specific individual. You should make your own decisions and seek independent professional advice before doing so. Remember: Shares can go down as well as up. Past performance is not a guide to future performance & investors may not get back the amount invested.
Share Price
2650p
Change Today
0.42%
Hikma Pharmaceuticals ( )

Stockopedia is here to help individual investors beat the markets by being the very best in stock analysis, research & community. Take a 30 day free trial of our extensive multi-award winning service and find out why more than ten thousand global investors can't live without it.

© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.